Cover Image
Market Research Report

North America Cancer Immunotherapy Market (2018 - 2024)

Published by KBV Research Product code 763724
Published Content info 77 Pages
Delivery time: 1-2 business days
Price
Back to Top
North America Cancer Immunotherapy Market (2018 - 2024)
Published: December 20, 2018 Content info: 77 Pages
Description

The North America Cancer Immunotherapy Market would witness market growth of 13.1% CAGR during the forecast period (2018 - 2024). Cancer immunotherapy is the type of cancer treatment helping the immune system fight cancer. There are various kinds of cancer immunotherapies used and they are monoclonal antibody, therapeutic cancer vaccines, checkpoint inhibitors, cytokines, and others. Growing patient population that is suffering from different types of cancer such as lung cancer, breast cancer, ovarian cancer, and other cancers are the factors that drive the global cancer immunotherapy market. Additionally, growing geriatric population and governmental contribution to healthcare expenditure are some other factors that add to the market growth.

Based on technology, the market is segmented into Monoclonal Antibodies, Cytokines & Immunomodulators and other technology. Based on application, the market is segmented into Lung cancer, Breast cancer, Colorectal, Prostate cancer, Head & Neck cancer and other application. Based on end user the market is segmented into Hospitals, Clinics and other end user. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca, Amgen Inc., Eli Lilly and Company, Merck & Co., Inc., Bristol-Myers Squibb Company, Pfizer Inc., Bayer Ag, Immunomedics Inc., Novartis AG, F. Hoffmann-La Roche Ltd

Table of Contents

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 North America Cancer Immunotherapy Market, by Technology
    • 1.4.2 North America Cancer Immunotherapy Market, by Application
    • 1.4.3 North America Cancer Immunotherapy Market, by End User
    • 1.4.4 North America Cancer Immunotherapy Market, by Geography
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. North America Cancer Immunotherapy Market by Technology

    • 3.1.1 North America Monoclonal Antibodies Cancer Immunotherapy Market by Country
    • 3.1.2 North America Cytokines & Immunomodulators Cancer Immunotherapy Market by Country
    • 3.1.3 North America Other Technology Cancer Immunotherapy Market by Country

Chapter 4. North America Cancer Immunotherapy Market by Application

    • 4.1.1 North America Cancer Immunotherapy Lung Cancer Market by Country
    • 4.1.2 North America Cancer Immunotherapy Breast Cancer Market by Country
    • 4.1.3 North America Cancer Immunotherapy Colorectal Cancer Market by Country
    • 4.1.4 North America Cancer Immunotherapy Melanoma Market by Country
    • 4.1.5 North America Cancer Immunotherapy Prostate Cancer Market by Country
    • 4.1.6 North America Cancer Immunotherapy Head & Neck Cancer Market by Country
    • 4.1.7 North America Other Application Cancer Immunotherapy Market by Country

Chapter 5. North America Cancer Immunotherapy Market by End User

    • 5.1.1 North America Hospitals Cancer Immunotherapy Market by Country
    • 5.1.2 North America Clinics Cancer Immunotherapy Market by Country
    • 5.1.3 North America Other End User Cancer Immunotherapy Market by Country

Chapter 6. North America Cancer Immunotherapy Market by Country

  • 6.1 US Cancer Immunotherapy Market
    • 6.1.1 US Cancer Immunotherapy Market by Technology
    • 6.1.2 US Cancer Immunotherapy Market by Application
    • 6.1.3 US Cancer Immunotherapy Market by End User
  • 6.2 Canada Cancer Immunotherapy Market
    • 6.2.1 Canada Cancer Immunotherapy Market by Technology
    • 6.2.2 Canada Cancer Immunotherapy Market by Application
    • 6.2.3 Canada Cancer Immunotherapy Market by End User
  • 6.3 Mexico Cancer Immunotherapy Market
    • 6.3.1 Mexico Cancer Immunotherapy Market by Technology
    • 6.3.2 Mexico Cancer Immunotherapy Market by Application
    • 6.3.3 Mexico Cancer Immunotherapy Market by End User
  • 6.4 Rest of North America Cancer Immunotherapy Market
    • 6.4.1 Rest of North America Cancer Immunotherapy Market by Technology
    • 6.4.2 Rest of North America Cancer Immunotherapy Market by Application
    • 6.4.3 Rest of North America Cancer Immunotherapy Market by End User

Chapter 7. Company Profiles

  • 7.1 Amgen Inc.
    • 7.1.1 Company Overview
    • 7.1.2 Financial Analysis
    • 7.1.3 Segmental & Regional Analysis
    • 7.1.4 Research and Development Expense
  • 7.2 Merck & Company, Inc.
    • 7.2.1 Company Overview
    • 7.2.2 Financial Analysis
    • 7.2.3 Regional and Segmental Analysis
    • 7.2.4 Research & Development
  • 7.3 Pfizer Inc.
    • 7.3.1 Company Overview
    • 7.3.2 Financial Analysis
    • 7.3.3 Segmental &Regional Analysis
    • 7.3.4 Revenue analysis by Region
    • 7.3.5 Research and Development
  • 7.4 Immunomedics Inc.
    • 7.4.1 Company Overview
    • 7.4.2 Financial Analysis
    • 7.4.3 Revenue Analysis by Region
    • 7.4.4 Research and Development
  • 7.5 Astrazeneca Plc.
    • 7.5.1 Company Overview
    • 7.5.2 Financial Analysis
    • 7.5.3 Segmental analysis
    • 7.5.4 Research & Development
  • 7.6 F. Hoffmann-La Roche Ltd.
    • 7.6.1 Company Overview
    • 7.6.2 Financial Analysis
    • 7.6.3 Revenue & Segment analysis
    • 7.6.4 Research and Development
  • 7.7 Eli Lilly and Company
    • 7.7.1 Company Overview
    • 7.7.2 Financial Analysis
    • 7.7.3 Segmental and Regional Analysis
    • 7.7.4 Research & Development Expense
  • 7.8 Novartis AG
    • 7.8.1 Company Overview
    • 7.8.2 Financial Analysis
    • 7.8.3 Segmental and Regional Analysis
    • 7.8.4 Research & Development Expense
  • 7.9 Bristol-Myers Squibb Company
    • 7.9.1 Company Overview
  • 7.1 Bayer AG
    • 7.10.1 Company Overview
    • 7.10.2 Financial Analysis
    • 7.10.3 Segmental and Regional Analysis
    • 7.10.4 Research & Development Expense

LIST OF TABLES

  • TABLE 1 NORTH AMERICA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 2 NORTH AMERICA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 3 NORTH AMERICA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 4 NORTH AMERICA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 5 NORTH AMERICA MONOCLONAL ANTIBODIES CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 6 NORTH AMERICA MONOCLONAL ANTIBODIES CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 7 NORTH AMERICA CYTOKINES & IMMUNOMODULATORS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 8 NORTH AMERICA CYTOKINES & IMMUNOMODULATORS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 9 NORTH AMERICA OTHER TECHNOLOGY CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 10 NORTH AMERICA OTHER TECHNOLOGY CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 11 NORTH AMERICA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 12 NORTH AMERICA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 13 NORTH AMERICA CANCER IMMUNOTHERAPY LUNG CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 14 NORTH AMERICA CANCER IMMUNOTHERAPY LUNG CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 15 NORTH AMERICA CANCER IMMUNOTHERAPY BREAST CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 16 NORTH AMERICA CANCER IMMUNOTHERAPY BREAST CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 17 NORTH AMERICA CANCER IMMUNOTHERAPY COLORECTAL CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 18 NORTH AMERICA CANCER IMMUNOTHERAPY COLORECTAL CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 19 NORTH AMERICA CANCER IMMUNOTHERAPY MELANOMA MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 20 NORTH AMERICA CANCER IMMUNOTHERAPY MELANOMA MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 21 NORTH AMERICA CANCER IMMUNOTHERAPY PROSTATE CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 22 NORTH AMERICA CANCER IMMUNOTHERAPY PROSTATE CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 23 NORTH AMERICA CANCER IMMUNOTHERAPY HEAD & NECK CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 24 NORTH AMERICA CANCER IMMUNOTHERAPY HEAD & NECK CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 25 NORTH AMERICA OTHER APPLICATION CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 26 NORTH AMERICA OTHER APPLICATION CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 27 NORTH AMERICA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 28 NORTH AMERICA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 29 NORTH AMERICA HOSPITALS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 30 NORTH AMERICA HOSPITALS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 31 NORTH AMERICA CLINICS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 32 NORTH AMERICA CLINICS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 33 NORTH AMERICA OTHER END USER CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 34 NORTH AMERICA OTHER END USER CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 35 NORTH AMERICA CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 36 NORTH AMERICA CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 37 US CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 38 US CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 39 US CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 40 US CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 41 US CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 42 US CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 43 US CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 44 US CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 45 CANADA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 46 CANADA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 47 CANADA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 48 CANADA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 49 CANADA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 50 CANADA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 51 CANADA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 52 CANADA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 53 MEXICO CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 54 MEXICO CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 55 MEXICO CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 56 MEXICO CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 57 MEXICO CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 58 MEXICO CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 59 MEXICO CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 60 MEXICO CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 61 REST OF NORTH AMERICA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 62 REST OF NORTH AMERICA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 63 REST OF NORTH AMERICA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 64 REST OF NORTH AMERICA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 65 REST OF NORTH AMERICA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 66 REST OF NORTH AMERICA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 67 REST OF NORTH AMERICA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 68 REST OF NORTH AMERICA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 69 KEY INFORMATION-AMGEN INC.
  • TABLE 70 KEY INFORMATION-MERCK & COMPANY INC.
  • TABLE 71 KEY INFORMATION- PFIZER INC.
  • TABLE 72 KEY INFORMATION- IMMUNOMEDICS INC.
  • TABLE 73 KEY INFORMATION- ASTRAZENECA PLC.
  • TABLE 74 KEY INFORMATION- F. HOFFMANN-LA ROCHE LTD.
  • TABLE 75 KEY INFORMATION - ELI LILLY AND COMPANY
  • TABLE 76 KEY INFORMATION - NOVARTIS AG
  • TABLE 77 KEY INFORMATION - BRISTOL-MYERS SQUIBB COMPANY
  • TABLE 78 KEY INFORMATION - BAYER AG
Back to Top